Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (231-240 of 440) with videos related to

Pageof 44
Sort By:
Molecular and Cellular Biology|October 5, 2011
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cellsJun Fan, Taro Hitosugi, Tae-Wook Chung, et al.
Cell Reports. Medicine|May 22, 2024
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myelomaMichael Amatangelo, Erin Flynt, Nicholas Stong, et al.
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Transfusion|May 26, 2012
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphomaJonathan L Kaufman, Christopher R Flowers, Karen D Rados, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2019
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple MyelomaSundar Jagannath, Leonard T Heffner, Sikander Ailawadhi, et al.
Cancer Cell|September 6, 2007
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathwaySumin Kang, Shaozhong Dong, Ting-Lei Gu, et al.
JCO Oncology Practice|July 7, 2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib InductionLaura F Sun, Kathryn T Maples, Kevin H Hall, et al.
Journal of the Advanced Practitioner in Oncology|October 9, 2023
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple MyelomaRakesh Popat, Sagar Lonial, Peter M Voorhees, et al.
Cancer|April 27, 2012
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomasRajni Sinha, Jonathan L Kaufman, Hanna Jean Khoury, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 22, 2020
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaJonathan L Kaufman, Roberto Mina, Jatin J Shah, et al.
Pageof 44

Showing results (231-240 of 440) with videos related to

Sort By:
Pageof 44
Molecular and Cellular Biology|October 5, 2011
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cellsJun Fan, Taro Hitosugi, Tae-Wook Chung, et al.
Cell Reports. Medicine|May 22, 2024
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myelomaMichael Amatangelo, Erin Flynt, Nicholas Stong, et al.
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Transfusion|May 26, 2012
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphomaJonathan L Kaufman, Christopher R Flowers, Karen D Rados, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2019
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple MyelomaSundar Jagannath, Leonard T Heffner, Sikander Ailawadhi, et al.
Cancer Cell|September 6, 2007
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathwaySumin Kang, Shaozhong Dong, Ting-Lei Gu, et al.
JCO Oncology Practice|July 7, 2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib InductionLaura F Sun, Kathryn T Maples, Kevin H Hall, et al.
Journal of the Advanced Practitioner in Oncology|October 9, 2023
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple MyelomaRakesh Popat, Sagar Lonial, Peter M Voorhees, et al.
Cancer|April 27, 2012
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomasRajni Sinha, Jonathan L Kaufman, Hanna Jean Khoury, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 22, 2020
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaJonathan L Kaufman, Roberto Mina, Jatin J Shah, et al.
Pageof 44